These include POLK, NIFK, SRGN, CAMP, CD109, and PLAC1 that are upregulated in several cancers resulting in metastasis and poor prognosis (Table 2, Fig
Changes in other risk factors associated with treatment (BMI, systolic blood pressure, LDL cholesterol, HDL cholesterol) were applied in the first year of analysis according to changes reported in SURPASS J-mono, and remained constant until switching treatment, at which point they returned to baseline (Table 2) [18]
This has led to the development of oral alternatives
Studies have shown it to be effective for functional constipation, IBS, and post-surgical digestive recovery
First-time prescribing of AOMs increased slightly in June 2024, compared to March 2024 (+7.26%)
no hierarchy is implied)